Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYSTONE-001: Pembrolizumab plus chemotherapy for esophageal squamous cell carcinoma
NCT04389177Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2020
- Primary completion
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoints: Major Pathologic Response at 3 months and Safety and Adverse Events up to 24 months. Status: unknown.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04389177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04389177.